
### [MONDO:0017255](http://purl.obolibrary.org/obo/MONDO_0017255)
**Label:** panuveitis (disease)

**Subclasses:** [MONDO:0018305](http://purl.obolibrary.org/obo/MONDO_0018305) (chronic granulomatous disease), [MONDO:0007191](http://purl.obolibrary.org/obo/MONDO_0007191) (Behcet's syndrome), [MONDO:0017258](http://purl.obolibrary.org/obo/MONDO_0017258) (idiopathic panuveitis), [MONDO:0001709](http://purl.obolibrary.org/obo/MONDO_0001709) (hypercalcemic sarcoidosis), [MONDO:0019338](http://purl.obolibrary.org/obo/MONDO_0019338) (sarcoidosis), [MONDO:0017211](http://purl.obolibrary.org/obo/MONDO_0017211) (infectious panuveitis), [MONDO:0001706](http://purl.obolibrary.org/obo/MONDO_0001706) (cerebral sarcoidosis), [MONDO:0001708](http://purl.obolibrary.org/obo/MONDO_0001708) (pulmonary sarcoidosis), [MONDO:0009310](http://purl.obolibrary.org/obo/MONDO_0009310) (granulomatous disease, chronic, autosomal recessive, cytochrome b-positive, type 2), [MONDO:0001707](http://purl.obolibrary.org/obo/MONDO_0001707) (cardiac sarcoidosis), [MONDO:0008523](http://purl.obolibrary.org/obo/MONDO_0008523) (Blau syndrome), [MONDO:0012281](http://purl.obolibrary.org/obo/MONDO_0012281) (sarcoidosis, early-onset), [MONDO:0001424](http://purl.obolibrary.org/obo/MONDO_0001424) (sarcoid meningitis), [MONDO:0018092](http://purl.obolibrary.org/obo/MONDO_0018092) (Vogt-Koyanagi-Harada disease), [MONDO:0006611](http://purl.obolibrary.org/obo/MONDO_0006611) (skin sarcoidosis), [MONDO:0007684](http://purl.obolibrary.org/obo/MONDO_0007684) (granulomatous disease, chronic, autosomal dominant type), [MONDO:0016206](http://purl.obolibrary.org/obo/MONDO_0016206) (idiopathic uveal effusion syndrome), [MONDO:0010600](http://purl.obolibrary.org/obo/MONDO_0010600) (granulomatous disease, chronic, X-linked), [MONDO:0012889](http://purl.obolibrary.org/obo/MONDO_0012889) (SS3), [MONDO:0012888](http://purl.obolibrary.org/obo/MONDO_0012888) (sarcoidosis, susceptibility to, 2), [MONDO:0008399](http://purl.obolibrary.org/obo/MONDO_0008399) (sarcoidosis, susceptibility to, 1), [MONDO:0017261](http://purl.obolibrary.org/obo/MONDO_0017261) (systemic diseases with panuveitis), [MONDO:0009307](http://purl.obolibrary.org/obo/MONDO_0009307) (granulomatous disease with defect 1N neutrophil chemotaxis), [MONDO:0009308](http://purl.obolibrary.org/obo/MONDO_0009308) (granulomatous disease, chronic, autosomal recessive, cytochrome b-negative), [MONDO:0009309](http://purl.obolibrary.org/obo/MONDO_0009309) (granulomatous disease, chronic, autosomal recessive, cytochrome b-positive, type 1), [MONDO:0007011](http://purl.obolibrary.org/obo/MONDO_0007011) (uveoparotid fever), [MONDO:0013507](http://purl.obolibrary.org/obo/MONDO_0013507) (granulomatous disease, chronic, autosomal recessive, cytochrome b-positive, type 3), 

**Mapped go classes:** [GO:0042613](http://purl.obolibrary.org/obo/GO_0042613) (MHC class II protein complex), [GO:0006955](http://purl.obolibrary.org/obo/GO_0006955) (immune response), [GO:0046982](http://purl.obolibrary.org/obo/GO_0046982) (protein heterodimerization activity), [GO:0016491](http://purl.obolibrary.org/obo/GO_0016491) (oxidoreductase activity), [GO:0048246](http://purl.obolibrary.org/obo/GO_0048246) (macrophage chemotaxis), [GO:0016175](http://purl.obolibrary.org/obo/GO_0016175) (superoxide-generating NADPH oxidase activity), [GO:0016176](http://purl.obolibrary.org/obo/GO_0016176) (superoxide-generating NADPH oxidase activator activity), [GO:0051607](http://purl.obolibrary.org/obo/GO_0051607) (defense response to virus), [GO:0019882](http://purl.obolibrary.org/obo/GO_0019882) (antigen processing and presentation), [GO:0008180](http://purl.obolibrary.org/obo/GO_0008180) (COP9 signalosome), [GO:0050832](http://purl.obolibrary.org/obo/GO_0050832) (defense response to fungus), [GO:0019886](http://purl.obolibrary.org/obo/GO_0019886) (antigen processing and presentation of exogenous peptide antigen via MHC class II), [GO:0008150](http://purl.obolibrary.org/obo/GO_0008150) (biological_process), [GO:0034341](http://purl.obolibrary.org/obo/GO_0034341) (response to interferon-gamma), [GO:0005086](http://purl.obolibrary.org/obo/GO_0005086) (ARF guanyl-nucleotide exchange factor activity), [GO:0042981](http://purl.obolibrary.org/obo/GO_0042981) (regulation of apoptotic process), [GO:0045730](http://purl.obolibrary.org/obo/GO_0045730) (respiratory burst), [GO:0042102](http://purl.obolibrary.org/obo/GO_0042102) (positive regulation of T cell proliferation), [GO:0042742](http://purl.obolibrary.org/obo/GO_0042742) (defense response to bacterium), [GO:0006810](http://purl.obolibrary.org/obo/GO_0006810) (transport), [GO:0002376](http://purl.obolibrary.org/obo/GO_0002376) (immune system process), [GO:0005765](http://purl.obolibrary.org/obo/GO_0005765) (lysosomal membrane), [GO:0005886](http://purl.obolibrary.org/obo/GO_0005886) (plasma membrane), [GO:0031902](http://purl.obolibrary.org/obo/GO_0031902) (late endosome membrane), [GO:0005515](http://purl.obolibrary.org/obo/GO_0005515) (protein binding), [GO:0006801](http://purl.obolibrary.org/obo/GO_0006801) (superoxide metabolic process), [GO:0046872](http://purl.obolibrary.org/obo/GO_0046872) (metal ion binding), [GO:0071800](http://purl.obolibrary.org/obo/GO_0071800) (podosome assembly), [GO:0009055](http://purl.obolibrary.org/obo/GO_0009055) (electron transfer activity), [GO:0042554](http://purl.obolibrary.org/obo/GO_0042554) (superoxide anion generation), [GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component), [GO:0003674](http://purl.obolibrary.org/obo/GO_0003674) (molecular_function), [GO:0002102](http://purl.obolibrary.org/obo/GO_0002102) (podosome), [GO:0000166](http://purl.obolibrary.org/obo/GO_0000166) (nucleotide binding), [GO:0005524](http://purl.obolibrary.org/obo/GO_0005524) (ATP binding), [GO:1990266](http://purl.obolibrary.org/obo/GO_1990266) (neutrophil migration), [GO:0005802](http://purl.obolibrary.org/obo/GO_0005802) (trans-Golgi network), [GO:0070062](http://purl.obolibrary.org/obo/GO_0070062) (extracellular exosome), [GO:0016192](http://purl.obolibrary.org/obo/GO_0016192) (vesicle-mediated transport), [GO:1900042](http://purl.obolibrary.org/obo/GO_1900042) (positive regulation of interleukin-2 secretion), [GO:0035091](http://purl.obolibrary.org/obo/GO_0035091) (phosphatidylinositol binding), [GO:0006355](http://purl.obolibrary.org/obo/GO_0006355) (regulation of transcription, DNA-templated), [GO:0005102](http://purl.obolibrary.org/obo/GO_0005102) (receptor binding), [GO:0020037](http://purl.obolibrary.org/obo/GO_0020037) (heme binding), [GO:0009617](http://purl.obolibrary.org/obo/GO_0009617) (response to bacterium), [GO:0050860](http://purl.obolibrary.org/obo/GO_0050860) (negative regulation of T cell receptor signaling pathway), [GO:0043020](http://purl.obolibrary.org/obo/GO_0043020) (NADPH oxidase complex), [GO:0097038](http://purl.obolibrary.org/obo/GO_0097038) (perinuclear endoplasmic reticulum), [GO:0005737](http://purl.obolibrary.org/obo/GO_0005737) (cytoplasm), [GO:0002504](http://purl.obolibrary.org/obo/GO_0002504) (antigen processing and presentation of peptide or polysaccharide antigen via MHC class II), [GO:0016020](http://purl.obolibrary.org/obo/GO_0016020) (membrane), [GO:0006909](http://purl.obolibrary.org/obo/GO_0006909) (phagocytosis), [GO:0016021](http://purl.obolibrary.org/obo/GO_0016021) (integral component of membrane), [GO:0055114](http://purl.obolibrary.org/obo/GO_0055114) (oxidation-reduction process), [GO:0050700](http://purl.obolibrary.org/obo/GO_0050700) (CARD domain binding), 

**Class expressions from DL-Learner:**

- Thing 52.79%
- [GO:0070062](http://purl.obolibrary.org/obo/GO_0070062) (extracellular exosome) 52.63%
- [GO:1903561](http://purl.obolibrary.org/obo/GO_1903561) (extracellular vesicle) 37.99%
- [GO:1903561](http://purl.obolibrary.org/obo/GO_1903561) (extracellular vesicle) and ([GO:0005012](http://purl.obolibrary.org/obo/GO_0005012) (obsolete Neu/ErbB-2 receptor activity) or [GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component)) 37.99%
- [GO:1903561](http://purl.obolibrary.org/obo/GO_1903561) (extracellular vesicle) and ([GO:0004988](http://purl.obolibrary.org/obo/GO_0004988) (obsolete mu-opioid receptor activity) or [GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component)) 37.99%
- [GO:1903561](http://purl.obolibrary.org/obo/GO_1903561) (extracellular vesicle) and ([GO:0004987](http://purl.obolibrary.org/obo/GO_0004987) (obsolete kappa-opioid receptor activity) or [GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component)) 37.99%
- [GO:1903561](http://purl.obolibrary.org/obo/GO_1903561) (extracellular vesicle) and ([GO:0004986](http://purl.obolibrary.org/obo/GO_0004986) (obsolete delta-opioid receptor activity) or [GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component)) 37.99%
- [GO:1903561](http://purl.obolibrary.org/obo/GO_1903561) (extracellular vesicle) and ([GO:0004981](http://purl.obolibrary.org/obo/GO_0004981) (null) or [GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component)) 37.99%
- [GO:1903561](http://purl.obolibrary.org/obo/GO_1903561) (extracellular vesicle) and ([GO:0004976](http://purl.obolibrary.org/obo/GO_0004976) (null) or [GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component)) 37.99%
- [GO:1903561](http://purl.obolibrary.org/obo/GO_1903561) (extracellular vesicle) and ([GO:0004975](http://purl.obolibrary.org/obo/GO_0004975) (null) or [GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component)) 37.99%
- [GO:1903561](http://purl.obolibrary.org/obo/GO_1903561) (extracellular vesicle) and ([GO:0004973](http://purl.obolibrary.org/obo/GO_0004973) (obsolete N-methyl-D-aspartate receptor-associated protein activity) or [GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component)) 37.99%
- [GO:1903561](http://purl.obolibrary.org/obo/GO_1903561) (extracellular vesicle) and ([GO:0004959](http://purl.obolibrary.org/obo/GO_0004959) (null) or [GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component)) 37.99%
- [GO:1903561](http://purl.obolibrary.org/obo/GO_1903561) (extracellular vesicle) and ([GO:0004944](http://purl.obolibrary.org/obo/GO_0004944) (null) or [GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component)) 37.99%
- [GO:1903561](http://purl.obolibrary.org/obo/GO_1903561) (extracellular vesicle) and ([GO:0004943](http://purl.obolibrary.org/obo/GO_0004943) (null) or [GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component)) 37.99%
- [GO:1903561](http://purl.obolibrary.org/obo/GO_1903561) (extracellular vesicle) and ([GO:0004942](http://purl.obolibrary.org/obo/GO_0004942) (null) or [GO:0005575](http://purl.obolibrary.org/obo/GO_0005575) (cellular_component)) 37.99%


